Washington D.C.[US], Oct. 18 (ANI
): Anti-inflammatory drugs
similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, finds a recent research led by the University of Cambridge.
Researchers analyzed data from 20 clinical trials involving the use of anti-cytokine drugs to treat a range of autoimmune inflammatory diseases.
By looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.
Meta-analyses of the other types of clinical trials showed similar results.
When we are exposed to an infection, for example influenza or a stomach bug, our immune system fights back to control and remove the infection.
During this process, immune cells flood the blood stream with proteins known as cytokines.
This process is known as systemic inflammation.
Even when we are healthy, our bodies carry trace levels of these proteins - known as 'inflammatory markers' - which rise exponentially in response to infection.
Previous work from the team found that children with high everyday levels of one of these markers are at greater risk of developing depression and psychosis in adulthood, suggesting a role for the immune system, particularly chronic low-grade systemic inflammation, in mental illness.
Inflammation can also occur as a result of the immune system mistaking healthy cells for infected cells and attacking the body, leading to autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
New types of anti-inflammatory drugs called anti-cytokine monoclonal antibodies and cytokine inhibitors have been developed recently, some of which are now routinely used for patients who respond poorly to conventional treatments.
Many more are currently undergoing clinical trials to test their efficacy and safety.
The team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.
In other words, regardless of whether a drug successfully treated rheumatoid arthritis, for example, it would still help improve a patient's depressive symptoms
. Their results are published today in the journal Molecular Psychiatry.
Golam Khandaker, the lead researcher said, "It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs. These are not your everyday anti-inflammatory drugs such as ibuprofen, however, but a particular new class of drugs."
"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however," added the co-author of the study.
"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease. On top of this, some existing drugs can have potentially serious side effects, which would need to be addressed," he said.
The team believed that anti-inflammatory drugs may offer hope for patients for whom current antidepressants are ineffective.
Although the trials reviewed by the team involve physical illnesses that trigger inflammation - and hence potentially contribute to depression - their previous work found a connection between depression and baseline levels of inflammation in healthy people (when someone does not have an acute infection), which can be caused by a number of factors such as genes and psychological stress.
"About a third of patients who are resistant to antidepressants show evidence of inflammation. So, anti-inflammatory treatments could be relevant for a large number of people who suffer from depression
," added Khandarker.
The research was published in Molecular Psychiatry journal. (ANI